Glucagon Reduces Neutrophil Migration and Increases Susceptibility to Sepsis in Diabetic Mice
| Autor: | Rafael L. Simões, Adriana Ribeiro Silva, Maximiliano Ruben Ferrero, Amanda da Silva Chaves, Daniella Bianchi Reis Insuela, Adriano Y. O. Silva, Thereza Christina Barja-Fidalgo, Patrícia M.R. e Silva, Vinicius F. Carvalho, Marco A. Martins, Hugo Caire Castro-Faria-Neto, Cassiano Felippe Gonçalves-de-Albuquerque |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Neutrophils Immunology Mice Inbred Strains Glucagon Diabetes Mellitus Experimental Sepsis sepsis Mice 03 medical and health sciences Peritoneal cavity 0302 clinical medicine Cell Movement Internal medicine cAMP medicine Animals Humans Immunology and Allergy Interleukin 8 Original Research diabetes Chemistry neutrophil Chemotaxis RC581-607 medicine.disease Neutrophilia CXCL1 Chemotaxis Leukocyte 030104 developmental biology medicine.anatomical_structure Endocrinology glucagon Female Disease Susceptibility medicine.symptom Immunologic diseases. Allergy Glucagon receptor 030217 neurology & neurosurgery |
| Zdroj: | Frontiers in Immunology, Vol 12 (2021) Frontiers in Immunology |
| ISSN: | 1664-3224 |
| Popis: | Sepsis is one of the most common comorbidities observed in diabetic patients, associated with a deficient innate immune response. Recently, we have shown that glucagon possesses anti-inflammatory properties. In this study, we investigated if hyperglucagonemia triggered by diabetes might reduce the migration of neutrophils, increasing sepsis susceptibility. 21 days after diabetes induction by intravenous injection of alloxan, we induced moderate sepsis in Swiss-Webster mice through cecum ligation and puncture (CLP). The glucagon receptor (GcgR) antagonist des-his1-[Glu9]-glucagon amide was injected intraperitoneally 24h and 1h before CLP. We also tested the effect of glucagon on CXCL1/KC-induced neutrophil migration to the peritoneal cavity in mice. Neutrophil chemotaxisin vitrowas tested using transwell plates, and the expression of total PKA and phospho-PKA was evaluated by western blot. GcgR antagonist restored neutrophil migration, reduced CFU numbers in the peritoneal cavity and improved survival rate of diabetic mice after CLP procedure, however, the treatment did no alter hyperglycemia, CXCL1/KC plasma levels and blood neutrophilia. In addition, glucagon inhibited CXCL1/KC-induced neutrophil migration to the peritoneal cavity of non-diabetic mice. Glucagon also decreased the chemotaxis of neutrophils triggered by CXCL1/KC, PAF, or fMLPin vitro. The inhibitory action of glucagon occurred in parallel with the reduction of CXCL1/KC-induced actin polymerization in neutrophilsin vitro, but not CD11a and CD11b translocation to cell surface. The suppressor effect of glucagon on CXCL1/KC-induced neutrophil chemotaxisin vitrowas reversed by pre-treatment with GcgR antagonist and adenylyl cyclase or PKA inhibitors. Glucagon also increased PKA phosphorylation directly in neutrophilsin vitro. Furthermore, glucagon impaired zymosan-A-induced ROS production by neutrophilsin vitro. Human neutrophil chemotaxis and adherence to endothelial cellsin vitrowere inhibited by glucagon treatment. According to our results, this inhibition was independent of CD11a and CD11b translocation to neutrophil surface or neutrophil release of CXCL8/IL-8. Altogether, our results suggest that glucagon may be involved in the reduction of neutrophil migration and increased susceptibility to sepsis in diabetic mice. This work collaborates with better understanding of the increased susceptibility and worsening of sepsis in diabetics, which can contribute to the development of new effective therapeutic strategies for diabetic septic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|